Dalbavancin / Oritavancin / Telavancin is a lipoglycopeptide antibiotics. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.
Regulatory status
Dalbavancin / Oritavancin / Telavancin has an FDA-approved product on the U.S. market, marketed as Dalbavancin under application ANDA219465.
The current label is held by Teva Pharmaceuticals, Inc.
From the FDA label
albavancin for injection is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dalbavancin for injection and other antibacterial drugs, dalbavancin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.Quoted from the FDA-approved prescribing information
The evidence
One source on Dalbavancin / Oritavancin / Telavancin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Dalbavancin / Oritavancin / Telavancin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides